Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
2021 · New England Journal of Medicine · 828 citations
https://doi.org/10.1056/nejmoa2103485
J
Josep M. Piulats
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
420
Papers
14.5K
Citations
49
h-index
118
i10-index
Josep M. Piulats is an academic researcher from Institut Català d'Ornitologia. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Cancer Immunotherapy and Biomarkers & PARP inhibition in cancer therapy. The author has an h-index of 49, co-authored 357 publications.
ORCID: 0000-0002-3606-1724Papers by this author
worksPembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
2019 · Journal of Clinical Oncology · 679 citations
https://doi.org/10.1200/jco.19.01638
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies
2016 · Cancer · 367 citations
https://doi.org/10.1002/cncr.30258
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
2024 · The Lancet · 211 citations
https://doi.org/10.1016/s0140-6736(24)01653-2
Molecular approaches for classifying endometrial carcinoma
2016 · Gynecologic Oncology · 187 citations
https://doi.org/10.1016/j.ygyno.2016.12.015
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
2021 · European Journal of Cancer · 173 citations
https://doi.org/10.1016/j.ejca.2020.12.023
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat